Publications by authors named "D Legallois"
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown. Our primary aim was to evaluate the risk of incident AF in patients exposed to ibrutinib compared to those exposed to acalabrutinib. Using the TriNetX research network database, we established a retrospective cohort of adult patients (≥ 18 years) previously diagnosed with a B-cell malignancy (using ICD-10-CM codes) in whom a first BTKi introduction occurred between January 1st, 2013 (first patient exposed to ibrutinib in TriNetX) and July 1st, 2024.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess how well dynamic SPECT with quantitative analysis of myocardial blood flow (MBF) and myocardial flow reserve (MFR) can detect coronary artery disease (CAD) in patients with new left bundle branch block (LBBB).
- The evaluation involved 174 patients with LBBB, finding SPECT abnormalities in only a small percentage, and highlighting a correlation between reduced MFR and fixed defects, although only a few patients had significant CAD after further examination.
- The conclusion suggests that routine screening for CAD in patients with presumed new LBBB may not be necessary, given the low incidence of actual CAD found.
Background: Early access experience in France with tafamidis meglumine, a selective transthyretin stabilizer for transthyretin-related amyloidosis cardiomyopathy (ATTR-CM), following transthyretin-related amyloidosis (ATTR) polyneuropathy approval and positive ATTR-ACT study results.
Aim: To describe the characteristics and clinical outcomes for patients in the French ATTR-CM tafamidis meglumine early access programme (28 Nov 2018 to 01 Jun 2021).
Methods: Patients with confirmed ATTR-CM received tafamidis meglumine 20mg/day or 80mg/day.
Article Synopsis
- The study investigates whether ibrutinib-related atrial fibrillation (IRAF) is linked to the dosage of ibrutinib, and if IRAF cases should lead to dosage adjustments or discontinuation of the drug.
- Researchers analyzed data from the World Health Organization's VigiBase® pharmacovigilance database, focusing on 1,162 IRAF cases and various dosing regimens of ibrutinib (ranging from 140 mg/day to over 560 mg/day).
- Results indicated that there was no significant association between the reported IRAF cases and the dosage of ibrutinib (p=0.09), suggesting IRAF is not a dose-dependent adverse drug reaction.
Rationale and design of the French Observatory of Acute Heart Failure (OFICA2).
Arch Cardiovasc Dis
September 2024
Background: Acute heart failure (AHF) is a leading cause of hospitalization and mortality - especially in patients aged≥65 years in high-income countries - and represents a high healthcare burden. In the past decade, the epidemiology and management of heart failure (HF) has changed, with the emergence of new medical and interventional therapeutics, but up-to-date real-life data are scarce.
Aims: The main objectives are to describe baseline characteristics (with an emphasis on lifestyle, cognitive status, HF knowledge and treatment adherence), management, and in-hospital and mid-term outcomes of AHF patients in France.